Prostate cancer: Genes, environment, immunity and the use of immunotherapy

Prostate Cancer and Prostatic Diseases

Volumn 11, Issue 3, 2008, Pages 230-236

  Karan, D ^a,b   Thrasher, J B ^a,b   Lubaroff, D ^c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GLUTATHIONE TRANSFERASE P1; GLYCOPROTEIN GP 100; HEPSIN; I KAPPA B KINASE ALPHA; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 12; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; MELAN A; MELANOMA ANTIGEN; MISMATCH REPAIR PROTEIN; MUCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; TOLL LIKE RECEPTOR 9; VIMENTIN;

AFRICAN AMERICAN; ASIAN; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RISK; CAUCASIAN; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIETARY INTAKE; DISEASE COURSE; DRUG TARGETING; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; HEREDITY; HUMAN; HUMORAL IMMUNITY; LIFESTYLE; MALE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; REVIEW; RISK REDUCTION; TUMOR IMMUNITY; UNITED STATES; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; DISEASE PROGRESSION; ENVIRONMENT; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; RISK FACTORS; TOLL-LIKE RECEPTOR 9;

EID: 50649089095     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2008.3     Document Type: Review

References (82)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. McCracken M, Olsen M, Chen Jr MS, Jemal A, Thun M, Cokkinides V et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 2007; 57: 190-205.
3. Ozanne SE, Constancia M. Mechanisms of disease: The developmental origins of disease and the role of the epigenotype. Nat Clin Pract Endocrinol Metab 2007; 3: 539-546.
4. Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 2006; 15: 2020-2026.
5. Botti C, Seregni E, Ferrari L, Martinetti A, Bombardieri E. Immunosuppressive factors: Role in cancer development and progression. Int J Biol Markers 1998; 13: 51-69.
6. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: A counterpoint. J Leukoc Biol 2005; 78 1043-1051.
7. Wolk A. Diet, lifestyle and risk of prostate cancer. Acta Oncol 2005; 44: 277-281.
8. Sonn GA, Aronson W, Litwin MS. Impact of diet on prostate cancer: A review. Prostate Cancer Prostatic Dis 2005; 8: 304-310.
9. Colditz GA, Sellers TA, Trapido E. Epidemiology - identifying the causes and preventability of cancer? Nat Rev Cancer 2006; 6: 75-83.
10. Monson RR, Christiani DC. Summary of the evidence: Occupation and environment and cancer. Cancer Causes Control 1997; 8: 529-531.
11. Gallagher RP, Fleshner N. Prostate cancer: 3. Individual risk factors. CMAJ 1998; 159: 807-813.
12. Drasch G, Schopfer J, Schrauzer GN. Selenium/cadmium ratios in human prostates: Indicators of prostate cancer risk of smokers and nonsmokers, and relevance to the cancer protective effects of selenium. Biol Trace Elem Res 2005; 103: 103-107.
13. De Vogli R, Ferrie JE, Chandola T, Kivimaki M, Marmot MG. Unfairness and health: Evidence from the Whitehall II Study. J Epidemiol Community Health 2007; 61: 513-518.
14. Karan D, Lin MF, Johansson SL, Batra SK. Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer 2003; 103: 285-293.
15. Isaacs WB. Molecular genetics of prostate cancer. Cancer Surv 1995; 25: 357-379.
16. Vecchione A, Gottardo F, Gomella LG, Wildemore B, Fassan M, Bragantini E et al. Molecular genetics of prostate cancer: Clinical translational opportunities. J Exp Clin Cancer Res 2007; 26: 25-37.
17. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S et al. Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA 2006; 103: 17337-17342.
18. Jovanovic M, Hengartner MO. miRNAs and apoptosis: RNAs to die for. Oncogene 2006; 25: 6176-6187.
19. Sen CK, Roy S. miRNA: Licensed to kill the messenger. DNA Cell Biol 2007; 26: 193-194.
20. Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 2007; 28: 2-12.
21. Kusenda B, Mraz M, Mayer J, Pospisilova S. MicroRNA biogenesis, functionality and cancer relevance. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006; 150: 205-215.
22. Wijnhoven BP, Michael MZ, Watson DI. MicroRNAs and cancer. Br J Surg 2007; 94: 23-30.
23. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med 2006; 12: 580-587.
24. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12.
25. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-6135.
26. Perera FP. Environment and cancer: Who are susceptible? Science 1997; 278: 1068-1073.
27. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12: 20-37.
28. Kabesch M, Lauener RP. Why Old McDonald had a farm but no allergies: genes, environments, and the hygiene hypothesis. J Leukoc Biol 2004; 75: 383-387.
29. Strachan DP. Hay fever, hygiene, and household size. Bmj 1989; 299: 1259-1260.
30. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 1997; 94: 11514-11519.
31. Condeelis J, Pollard JW. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266.
32. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269.
33. Karan D, Chen SJ, Johansson SL, Singh AP, Paralkar VM, Lin MF et al. Dysregulated expression of MIC-1/PDF in human prostate tumor cells. Biochem Biophys Res Commun 2003; 305: 598-604.
34. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 2007; 97: 557-561.
35. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005; 11: 3250-3256.
36. Nithipatikom K, Isbell MA, Lindholm PF, Kajdacsy-Balla A, Kaul S, Campell WB. Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis 2002; 19: 593-601.
37. Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002; 53: 232-240.
38. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007; 446: 690-694.
39. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: Possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004; 53: 844-854.
40. Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 2007; 56: 81-87.
41. Poggi A, Zocchi MR. Mechanisms of tumor escape: Role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp 2006; 54: 323-333.
42. Sadun RE, Sachsman SM, Chen X, Christenson KW, Morris WZ, Hu P et al. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res 2007; 13: 4016-4025.
43. Dupont B. Introduction: Current concepts in immunity to human cancer and therapeutic antitumor vaccines. Immunol Rev 2002; 188: 5-8.
44. Karan D, Krieg AM, Lubaroff DM. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer 2007; 121: 1520-1528.
45. Baral R. Tumor vaccine: Current trends in antigen specific immunotherapy. Indian J Exp Biol 2005; 43: 389-406.
46. Itoh K, Hayashi A, Toh Y, Imai Y, Yamada A, Nishida T et al. Development of cancer vaccine by tumor rejection antigens. Int Rev Immunol 1997; 14: 153-171.
47. Saenz-Badillos J, Amin SP, Granstein RD. RNA as a tumor vaccine: A review of the literature. Exp Dermatol 2001; 10: 143-154.
48. Schirrmacher V. Tumor vaccine design: Concepts, mechanisms, and efficacy testing. Int Arch Allergy Immunol 1995; 108: 340-344.
49. Dalgleish AG, Whelan MA. Cancer vaccines as a therapeutic modality: The long trek. Cancer Immunol Immunother 2006; 55: 1025-1032.
50. Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep 2007; 9: 226-233.
51. Kaminski JM, Summers JB, Ward MB, Huber MR, Minev B. Immunotherapy and prostate cancer. Cancer Treat Rev 2003; 29: 199-209.
52. McNeel DG. Prostate cancer immunotherapy. Curr Opin Urol 2007; 17: 175-181.
53. Minev BR, Guo F, Gueorguieva I, Kaiser HE. Vaccines for immunotherapy of breast cancer and prostate cancer: New developments and comparative aspects. In Vivo 2002; 16: 405-415.
54. Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer. Urol Oncol 2006; 24: 419-424.
55. Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer: A review of clinical data. Curr Opin Investig Drugs 2005; 6: 592-596.
56. Banchereau J, Fay J, Pascual V, Palucka AK. Dendritic cells: Controllers of the immune system and a new promise for immunotherapy. Novartis Found Symp 2003; 252: 226-235.
57. Boyd D, Hung CF, Wu TC. DNA vaccines for cancer. IDrugs 2003; 6 1155-1164.
58. Brossart P. Dendritic cells in vaccination therapies of malignant diseases. Transfus Apher Sci 2002; 27: 183-186.
59. Lubaroff DM, Karan D, Andrews MP, Acosta A, Abouassaly C, Sharma M et al. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine 2006; 24: 6155-6162.
60. Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 2002; 62: 5260-5266.
61. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90: 1894-1900.
62. Xia D, Moyana T, Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res 2006; 16: 241-259.
63. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 1996; 93: 7855-7860.
64. Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene 1998; 17: 3125-3135.
65. Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer 2001; 94: 842-849.
66. Lubaroff DM, Konety B, Link BK, Ratliff TL, Madsen T, Shannon M et al. Clinical protocol: Phase I study of an adenovirus/ prostate-specific antigen vaccine in men with metastatic prostate cancer. Hum Gene Ther 2006; 17: 220-229.
67. Krieg AM. CpG motifs: The active ingredient in bacterial extracts? Nat Med 2003; 9: 831-835.
68. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.
69. O'Neill L. Toll-like receptors and the danger hypothesis. Trends Immunol 2001; 22: 421.
70. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1-14.
71. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-484.
72. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34 251-262.
73. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117: 1184-1194.
74. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncol 2006; 8: 60-66.
75. Carpentier AF, Auf G, Delattre JY. CpG-oligonucleotides for cancer immunotherapy: Review of the literature and potential applications in malignant glioma. Front Biosci 2003; 8: E115-e127.
76. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4: 249-258.
77. Haddada H, Cordier L, Perricaudet M. Gene therapy using adenovirus vectors. Curr Top Microbiol Immunol 1995; 199: 297-306.
78. Jaffe HA, Danel C, Longenecker G, Metzger M, Setoguchi Y, Rosenfeld MA et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1992; 1: 372-378.
79. Salucci V, Mennuni C, Calvaruso F, Cerino R, Neuner P, Ciliberto G et al. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand. Scand J Immunol 2006; 63: 35-41.
80. Wingender G, Garbi N, Schumak B, Jungerkes F, Endl E, von Bubnoff D et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol 2006; 36: 12-20.
81. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 2005; 175: 5601-5605.
82. Offringa R. Cancer immunotherapy is more than a numbers game. Science 2006; 314: 68-69.